Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia

ObjectivesThe objective of this study is to report the dose response in ODYSSEY phase 3 clinical trials of proprotein convertase subtilisin kexin type 9 inhibition with alirocumab in patients not at prespecified lipid goals who received a per-protocol dose increase from 75 every 2 weeks (Q2W) to 150